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 Recent discussions regarding global access to 
innovations in health in developing countries 
have focused on intellectual property rights 
(IPR). 1 For example, IPR are embedded at 
each stage of vaccine development and access, 
including research (laboratory and clinical 
programs), appropriate regulations to ensure 
safety and effi cacy, manufacturing capabilities 
to meet international quality standards, 
licensing and international procurement. 2 
Indeed, although not the sole factor affecting 
access, IPR nevertheless are ubiquitous and 
important. 3 Management of IPR can be 
advanced via dynamic linkages, for example, 
public – private partnerships such as the 
International AIDS Vaccine Initiative. 4 Hence, 
IPR can be an impediment (restricting access) 
or an opportunity (creating linkages) 
depending on how they are managed. 
 Johanna Gibson ’ s  Intellectual Property, Medicine 
and Health: Current Debates is an ambitious 
attempt to bridge the gap between IPR 
(largely patents) and the ethical, moral and 
philosophical issues which should infl uence 
global access to innovations in health. 
This intent is noteworthy and timely, as the 
complexities are important to address and there 
is an urgent need for clear-headed strategy. 
However, disappointingly, the book largely 
fails, as it is a rambling polemic that lacks focus, 
clarity and originality. Wading through the 
thicket of verbiage becomes so daunting that 
whatever message might be present is lost. The 
book also is fl awed in its skewed interpretation 
of IP law and lack of forward vision. As such, 
it mostly stands as a rehashing of previous 
material, adding little in the way of new 
analyses or suggested strategic options. 
 The 223-page book is divided into four 
sections:  (1) Health: the life of health, the 
health of intellectual property;  (2) Rights: the 
human right to health, health development 
and culture, patent morality;  (3) Life: the 
technology of life, life ’ s libraries;  (4) Access: 
access, use. Each of these sections then 
expands on the topic; for example  ‘ rights ’ are 
further discussed as the right to self-
determination, right to access to medicine 
and the right to benefi t from one ’ s creativity. 
The author then juxtaposes these rights 
with IPR, drawing conclusions and making 
inferences about developing countries ’ access 
to innovations in health that might be true 
under certain circumstances, yet are largely 
skewed toward the presumed injustice of the 
global system of IPR, that is, how the North 
has weaponized IPR to further dominate the 
South. The author ’ s citing of notoriously 
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anti-IPR organizations, for example, 
RAFI (p. 129) and Greenpeace (p. 107), 
as authoritative, credible sources, further 
exacerbates this advocacy. 
 The book ’ s messages are often lost 
in a densely entangled mass of nearly 
incomprehensible prose. In addition, there 
is an annoying overuse of jargon (for example, 
 ‘ arguably ’ and  ‘ articulated ’ ), as if the spoken 
word had been directly dictated to text, with 
little or no independent editorial oversight in 
later drafts of the manuscript (assuming there 
 actually were later drafts ). Verbosity abounds, for 
example:  ‘ In other words, in place is a strict 
division between the material and objective 
nature of the intellectual property system with 
the subjectivity of moral rights rendered 
peripheral to the organic unity of that system. 
Thus, the social and legitimate agency of the 
actors within that system is deferred by the 
priority attached to the economic modeling of 
innovation and creativity ’ (p. 11). Wordiness 
is further coagulated by throat-clearing slang: 
 ‘ Signifi cantly, a cultural interrogation of the 
patent system precipitates recognition of the 
critical value of access to the intention of the 
system.  Arguably , this access value is  articulated 
through the concept of use within the patent 
framework ’ (p. 22) (italic emphasis added by 
reviewer). For subsequent works, it might 
be advisable to consult Strunk and White for 
guidance on concise writing. 5 
 Confusing legal discussion also appears. For 
example:  ‘ Therefore, although it is beyond the 
remit of an economic system of regulation to 
fulfi ll the ethical oversight of these fi elds of 
technology, the patent system features in the 
moral dilemma of biotechnology inventions. 
 Arguably , although often described to the 
contrary, it is not the  ownership as such but the 
authorship that is the critical antagonist in these 
debates ’ (p. 13) (italic emphasis added by 
reviewer). Patents have inventors, not  authors . 
Authors are for copyrighted works, for 
example, books. This is the same legally 
operative terminology in both US and UK 
patent law as well as the European Patent 
Offi ce. 
 Another example further illustrates 
the confused tone of the legal discussion:  
‘ The market is achieved by  imposing certain 
monopoly rights with respect to use, thus 
achieving an artifi cial scarcity on certain 
manifestations  ( fi xations) of information ’ (p. 24) 
(italic emphasis added by reviewer). There 
are two problems with this statement. First, 
patents are not monopolies  per se . Patents 
neither automatically confer market 
domination nor establish a cartel. To assert 
that patents confer monopolistic power defi es 
logic, as they protect inventions that are, 
by defi nition, new and hence cannot be 
 ‘ scarce ’ as they are novel in the fi rst instance. 
Patents simply confer property rights, albeit 
intangible. As per McCarthy:  ‘ Without a 
rigorous analysis and defi nition of the relevant 
economic market, one cannot say that the 
claims of all, or even many, patents defi ne a 
substantial portion of a true relevant market ’ . 6 
Puzzlingly, the book also has a section 
(p. 188) that addresses patent pools, and 
again uses the term  ‘ monopoly ’ ( ‘ Therefore, 
a patent pool can also create a monopoly 
over certain technology if competitors 
cooperate  … ’ ), yet fails to distinguish that 
use of the term from its ubiquitous (mis)use 
throughout the book. The second problem 
with the statement above is, once again, 
the confusion of copyright with patent 
terminology:  ‘ fi xations of information ’ are 
copyrighted (inventions are patented). 
 On page 115, US5567607 is incorrectly 
cited as the original patent on the Harvard 
Oncomouse. US5567607, a patent covering 
a method for producing transgenic animals, 
is assigned to Incel, was granted in 1996 
and is not connected via patent prosecution 
(nor even citation) to the original Oncomouse 
patent. The issue is further confused by the 
assertion that this method would cover the 
mice themselves (presumably as compositions 
of matter), which is wrong: it would only 
cover  the method . However, the error is truly 
glaring in that the correct original patent 
for Oncomice is US4736866 (inventors are 
Leder and Stewart; assignee is Harvard), 
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licensing, differential pricing and similar aid 
mechanisms. This perpetuates the notion 
that the hapless South will forever require 
assistance, always need to be rescued by 
well-meaning intellectuals of the North, and 
fosters a failed development agenda that 
stresses  ‘ special ’ assistance in lieu of solid, 
sustainable global partnerships. 
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which claims the transgenic animal as the 
invention. 7 Such poor research casts an 
overall shadow across the credibility of 
this book, and suggests that this was an 
early draft improperly accelerated into 
publication. 
 This book intimates that the industrialized 
North uses IPR to subjugate the developing 
South. However, it fails to consider that 
problems will continue until the South 
acquires the capacity and capability to assert 
its own interests, agendas and rights. Topics 
covered in the book should therefore be 
analyzed in the context of developing 
countries ’ stages of development, infrastructure, 
public health systems and technological 
sophistication. This can be a win-win scenario: 
wealth creates wealth, and rich trading partners 
create economic synergy. 8 Recent examples 
of rapidly developing economies support this, 
including India, China and Brazil. Sadly, 
this concept of development is only briefl y 
mentioned on page 136:  ‘ The opportunity 
to license with developing-country partners 
is recognized not only as a mechanism by 
which to avoid delays or failure to market 
but also as an important contribution to local 
innovation and development ’ . Similarly, the 
author mentions the Bonn Guidelines for 
the Convention on Biological Diversity (p. 76) 
but fails to suggest that the establishment of 
Competent National Authorities could facilitate 
equitable access and benefi t sharing provisions. 
This could have been effectively integrated 
into the discussion of access to avian infl uenza 
virus (H5N1) (p 74). Also, there is no 
mention of TRIPs Articles 66.2 or 67 
(obligating industrialized countries to assist 
developing countries in building capacity in 
technology transfer and intellectual property 
management). Many fascinating topics are 
touched upon, yet poorly analyzed. 
 The reader is left with a book that is 
fi lled with vague fi nger pointing, advocating 
a worn-out development agenda that relies 
on funds, trusts, donations, compulsory 
